Table 2.
Progression of clinical outcome assessments according to the study follow-up time in the overall HSP group and in the SPG4 subgroup.
| HSP group | SPG4 group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| COA | Assessment | Mean | 95% CI | p 1 | Statistical Difference (*) | Mean | 95% CI | p 1 | Statistical difference (*) |
| SPRS | Baseline | 18.3 | 14.8–21.9 | 0.030 | A | 17.27 | 12.5–22.0 | 0.018 | A |
| 1.5 years | 20 | 16.5–23.6 | AB | 19.7 | 15.1–24.3 | AB | |||
| 4.5 years | 20.3 | 16.9–23.7 | B | 19.7 | 15.5–23.9 | B | |||
| mSPRS | Baseline | 16.6 | 13.6–19.7 | 0.002 | A | 16 | 11.5–20.4 | 0.005 | A |
| 1.5 years | 17.5 | 14.2–20.9 | AB | 16.9 | 12.7–21.1 | AB | |||
| 4.5 years | 18.4 | 15.3–21.6 | B | 17.6 | 13.6–21.7 | B | |||
| 10MWT-SSWS—s | Baseline | 17.3 | 14.1–21.3 | <0.001 | AB | 17.2 | 12.8–23 | 0.006 | AB |
| 1.5 years | 16 | 13–19.7 | A | 16.4 | 12.2–21.8 | A | |||
| 4.5 years | 19.4 | 15.1–24.8 | B | 18.7 | 13.7–25.5 | B | |||
| 10MWT-MWS—s | Baseline | 12.4 | 10–16 | ns | A | 12.2 | 9.4–16.9 | ns | A |
| 1.5 years | 11.1 | 9.2–13.6 | A | 10.8 | 8.7–14 | A | |||
| 4.5 years | 11.9 | 9.4–16.1 | A | 11.3 | 8.7–15.6 | A | |||
| TUG-SSWS—s | Baseline | 20.3 | 16.3–25.3 | <0.001 | A | 18.7 | 14–24.9 | <0.001 | AB |
| 1.5 years | 19.5 | 15.4–24. | A | 17.7 | 13.5–23.3 | A | |||
| 4.5 years | 25 | 19.1–32.8 | B | 23.5 | 16.8–32.9 | B | |||
| TUG-MWS—s | Baseline | 16.1 | 12.8–20.3 | <0.001 | A | 14.7 | 10.6–19.8 | <0.001 | A |
| 1.5 years | 17.6 | 13.6–22.8 | A | 15.9 | 11.6–22 | A | |||
| 4.5 years | 22.6 | 16.9–29.9 | B | 20.6 | 14.2–29.7 | B | |||
| 6MWT—m | Baseline | 218.4 | 168.4–268.5 | 0.018 | A | 236.8 | 177.9–295.5 | <0.001 | A |
| 1.5 years | 209.1 | 157.5–260.6 | AB | 226.5 | 161.5–291.5 | A | |||
| 4.5 years | 175.2 | 126.6–223.8 | B | 178.5 | 161.5–291.5 | B | |||
| LRI—% | Baseline | 40 | 31.5–48.5 | <0.001 | AB | 44 | 31.7–56.3 | 0.008 | AB |
| 1.5 years | 42.3 | 32.9–51.8 | A | 45 | 32.6–56.8 | A | |||
| 4.5 years | 35.8 | 26.6–45.1 | B | 40 | 27.5–51.4 | B | |||
Data are shown as mean and 95% confidence intervals. Variables that did not have normal distribution were log-transformed, except for 10MWT-MWS which was Box-Cox transformed, for the analyses and back-transformed to raw values to be presented in the table. m, meters; s, seconds; COA, clinical outcome assessments; HSP, hereditary spastic paraplegia; LRI, locomotor rehabilitation index (%): percentage; 6MWT, 6-min walking test; SPRS, Spastic Paraplegia Rating Scale; mSPRS, Motor Spastic Paraplegia Rating Scale; 10MWT-SSWS, 10-meter walking test at self-selected speed; 10MWT-MWS (s), 10-meter walking test at maximal speeds; TUG-SSWS, Timed-Up and Go test at self-selected walking speed; TUG-MWS, Timed-Up and Go test at maximal walking speed. 1GEE test; Bonferroni post-hoc test. *The presence of different capital letters between the evaluation points indicates the presence of statistically significant differences. For instance, in the case of SPRS, baseline represented by A and 4.5 years by B indicate differences between these times, while the representation AB in 1.5 years indicates that there is no difference between this assessment and baseline or 4.5-year assessments.